Dr Reddys Laboratories Ltd 6-K, filed Jan 6, 2023
Dr Reddys Laboratories Ltd (RDY)
About this 6-K
Dr Reddys Laboratories Ltd filed this 6-K on January 6, 2023.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
January, 2023
Commission File Number 1-15182
DR. REDDY’S LABORATORIES LIMITED
(Translation of registrant’s name into English)
8-2-337, Road No. 3, Banjara Hills
Hyderabad, Telangana 500 034, India
+91-40-49002900
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ______
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ☐ No ☒
If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.
EXHIBITS
|
Exhibit |
Description of Exhibits | |
| 99.1 | Intimation dated January 6, 2023. | |
| 99.2 | Intimation dated January 6, 2023 regarding resignation of Independent Director | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| DR. REDDY’S LABORATORIES LIMITED (Registrant) | ||
| Date: January 6, 2023 | By: | /s/ K Randhir Singh |
| Name: | K Randhir Singh | |
| Title: | Company Secretary | |
Exhibit 99.1
 |
Dr. Reddy’s Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, CIN : L85195TG1984PLC004507
Tel : +91 40 4900 2900 Fax : +91 40 4900 2999 Email : mail@drreddys.com www.drreddys.com |
January 6, 2023
National Stock Exchange of India Ltd. (Scrip Code: DRREDDY-EQ)
BSE Limited (Scrip Code: 500124)
Dear Sirs,
Sub: Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Schedule of Analyst / Institutional Investor Meetings
This is to inform you that the Company’s management will be participating in the following group investor meeting:
| Date | Conference | Location | ||
| January 10, 2023 | J.P. Morgan Healthcare Conference | San Francisco, California, US |
Please note that the schedule of the aforesaid meeting is subject to change due to any exigencies on the part of Investors / Company.
This is for your information.
Thanking you.
Yours faithfully,
For Dr. Reddy’s Laboratories Limited
| /s/ K Randhir Singh | |
| K Randhir Singh |
Company Secretary, Compliance Officer and Head CSR
CC:- New York Stock Exchange Inc.(Stock Code :RDY)
NSE IFSC Ltd
Exhibit 99.2
 |
Dr. Reddy’s Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, CIN : L85195TG1984PLC004507
Tel : +91 40 4900 2900 Fax : +91 40 4900 2999 Email : mail@drreddys.com www.drreddys.com |
January 6, 2023
National Stock Exchange of India Ltd. (Scrip Code: DRREDDY-EQ)
BSE Limited (Scrip Code: 500124)
New York Stock Exchange Inc. (Stock Code :RDY)
NSE IFSC Ltd. (Stock Code: DRREDDY)
| Sub: | Disclosure under Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 – Resignation of an Independent Director |
Dear Sir/ Madam,
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations), this is to inform you that Mr. Allan Grant Oberman (DIN: 08393837), has tendered his resignation as an Independent Director of the Company, with effect from the close of business hours on January 6, 2023.
We annex herewith the letter of resignation with reason as indicated, received from Mr. Allan on January 6, 2023. Mr. Allan has resigned as an Independent Director of the Company as he will be moving into a commitment outside the Company that will not allow him to be able to devote sufficient time for his responsibilities as an Independent Director of the Company. Mr. Allan in his letter has also confirmed that there are no other material reasons for his resignation other than those mentioned in the resignation letter. Mr. Allan does not hold directorship in any other listed entities.
Further, we would like to inform that post resignation of Mr. Allan, as an Independent Director, the composition of the Board continues to be in compliance with the requirements of the Companies Act, 2013 and the SEBI Listing Regulations.
The details under Regulation 30 of the SEBI Listing Regulations read with SEBI Circular CIR/CFD/CMD/4/2015 dated September 9, 2015 are annexed herewith.
This is for your information and records.
Thanking you.
Yours truly,
For Dr. Reddy’s Laboratories Limited
| /s/ K Randhir Singh | |
| K Randhir Singh |
Company Secretary, Compliance Officer and Head – CSR
Encl: as above.
January 6, 2023
Mr. Satish Reddy,
Chairman
Dr. Reddy’s Laboratories Limited
8-2-337, Banjara Hills,
Road No. 3, Hyderabad 500 034,
Telangana, India
Dear Satish,
Please accept this as my letter of resignation as a member of the Board of Dr. Reddy’s Laboratories Limited as I will be moving into a commitment that will not allow me to be able to devote sufficient time for my responsibilities as an Independent Director of the Company.
It has been my pleasure and privilege to serve on the Board of the Company. I deeply appreciate and acknowledge the professionalism and support of my fellow colleagues on the Board and the management of Dr. Reddy’s during my tenure.
I further confirm that there are no other material reasons other than those provided above for my resignation as an independent director from the Board of the Company. Please also note that I do not hold directorship in any other listed entities. I have truly enjoyed my time serving as an Independent Director of this Company and wish you and the entire Company all the best.
Please treat this as my formal resignation with effect from the close of business hours on January 6, 2023 and do the regulatory communication as required.
| Best regards, | ||
 |
||
| Allan Oberman | ||
| (DIN: 08393837) |
| |
Dr. Reddy’s Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, CIN : L85195TG1984PLC004507
Tel : +91 40 4900 2900 Fax : +91 40 4900 2999 Email : mail@drreddys.com www.drreddys.com |
Annexure
Details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular CIR/CFD/CMD/4/2015 dated September 9, 2015
Details of Mr. Allan Grant Oberman
|
Sl No. |
Particulars | Remarks |
| 1 | Reason for change | Resignation on account of moving into a commitment outside the Company that will not allow him to be able to devote sufficient time for his responsibilities as an Independent Director of the Company. |
| 2 | Date of cessation as a Director | January 6, 2023 |
| 3 | Brief profile | Not applicable |
| 4 | Disclosure of relationships between directors | Not applicable |
